B-cell maturation antigen (BCMA) is widely expressed on the surface of mature B cells, normal and malignant plasma cells, but has low expression on other normal cells and no expression on CD34 + ...

Ichnos Glenmark Innovation subsidiary IGI Therapeutics has signed an exclusive licensing agreement with AbbVie for ISB 2001, ...

Market Trends, Business Strategies, Competitive Intelligence, Clinical Trials, and Patent Trends Driving Growth from 2024 to 2029"Boston, July 10, 2025 (GLOBE NEWSWIRE) -- According to the latest ...

ALLO-316 shows promising results in advanced renal cell carcinoma, with a 25% response rate and rapid treatment turnaround, ...

In recent years, the FDA has approved three complement inhibitors for gMG -- eculizumab (Soliris), ravulizumab (Ultomiris), ...

Chimeric antigen receptor (CAR) therapies utilize engineered receptors that are able to redirect immune cells to identify and destroy cancer cells that express a specific antigen. At present, CAR ...

Cancer Gene Therapy - Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them. Skip to main content. Thank you for visiting nature.com.

Background: Although chimeric antigen receptor (CAR)-T cells produce impressive outcomes in B-cell malignancies, a substantial fraction of patients with relapsed/refractory B-cell leukemia and ...

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, discussed the complexities of alternative payment models for ...